LAUSR

Patients with BCR-ABL negative chronic myeloproliferative neoplasms (MPNs) present with chronic kidney disease (CKD) in up to one third of cases. These patients are known to have increased cardiovascular risk and usually present with features of stronger myeloproliferation. In recent years CKD has gained attention in MPN patients as a potential renal manifestation of the disease termed MPN-related glomerulopathy. This view has been supported mainly by evidence from kidney biopsies and renal post-mortem autopsy findings of MPN patients, as well as by clinical observations of improvement/slower deterioration of renal function after institution of specific therapies in some MPN cohorts. All current evidence is based only on retrospective datasets which are known to be susceptible to different types of bias. Prospectively designed interventional studies are needed to properly understand true effects of CKD and its control by differently targeted (CKD and MPN directed) therapies.